Which has preferable valuation & earnings, DFTX or SPTX?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Seaport Therapeutics N/A N/A -$74.88M -$12.12 N/A

Is DFTX or SPTX more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Seaport Therapeutics N/A N/A N/A

Does the media favor DFTX or SPTX?

In the previous week, Definium Therapeutics had 30 more articles in the media than Seaport Therapeutics. MarketBeat recorded 44 mentions for Definium Therapeutics and 14 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.85 beat Definium Therapeutics' score of 0.29 indicating that Seaport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 8 Very Positive mention(s) 12 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 6 Very Negative mention(s) Neutral Seaport Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SPTX or INDV?

In the previous week, Seaport Therapeutics had 10 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Seaport Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.66 beat Seaport Therapeutics' score of 0.85 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, MANE or SPTX?

Veradermics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A Seaport Therapeutics N/A N/A -$74.88M -$12.12 N/A

Is MANE or SPTX more profitable?

Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Seaport Therapeutics N/A N/A N/A

Does the media favor MANE or SPTX?

In the previous week, Seaport Therapeutics had 12 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Seaport Therapeutics and 2 mentions for Veradermics. Veradermics' average media sentiment score of 1.48 beat Seaport Therapeutics' score of 0.85 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seaport Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TARS or SPTX?

In the previous week, Seaport Therapeutics had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 14 mentions for Seaport Therapeutics and 12 mentions for Tarsus Pharmaceuticals. Seaport Therapeutics' average media sentiment score of 0.85 beat Tarsus Pharmaceuticals' score of 0.62 indicating that Seaport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seaport Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OGN or SPTX?

In the previous week, Seaport Therapeutics had 8 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Seaport Therapeutics and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.05 beat Seaport Therapeutics' score of 0.85 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Seaport Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Seaport Therapeutics (SPTX) Competitors

$22.96 -1.74 (-7.04%)

As of 09/15/2026 04:00 PM Eastern

Compare

SPTX vs. DFTX, INDV, MANE, TARS, and OGN

Should you buy Seaport Therapeutics stock or one of its competitors? Seaport Therapeutics's main competitors and comparable companies include Definium Therapeutics (DFTX), Indivior (INDV), Veradermics (MANE), Tarsus Pharmaceuticals (TARS), and Organon & Co. (OGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Seaport Therapeutics compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Definium Therapeutics had 30 more articles in the media than Seaport Therapeutics. MarketBeat recorded 44 mentions for Definium Therapeutics and 14 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.85 beat Definium Therapeutics' score of 0.29 indicating that Seaport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	8 Very Positive mention(s)	12 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	6 Very Negative mention(s)	Neutral
Seaport Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics currently has a consensus target price of $64.88, indicating a potential upside of 76.20%. Seaport Therapeutics has a consensus target price of $37.33, indicating a potential upside of 62.60%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Definium Therapeutics is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

Definium Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Seaport Therapeutics' return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Seaport Therapeutics	N/A	N/A	N/A

Summary

Definium Therapeutics beats Seaport Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Seaport Therapeutics compare to Indivior?

Seaport Therapeutics (NASDAQ:SPTX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Seaport Therapeutics had 10 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Seaport Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.66 beat Seaport Therapeutics' score of 0.85 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

60.3% of Indivior shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Seaport Therapeutics currently has a consensus price target of $37.33, suggesting a potential upside of 62.60%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 31.99%. Given Seaport Therapeutics' higher possible upside, research analysts clearly believe Seaport Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Indivior has a net margin of 26.65% compared to Seaport Therapeutics' net margin of 0.00%. Seaport Therapeutics' return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Indivior	26.65%	-283.11%	36.85%

Indivior has higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Indivior	$1.24B	3.26	$210M	$2.79	12.27

Summary

Indivior beats Seaport Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Seaport Therapeutics compare to Veradermics?

Veradermics (NYSE:MANE) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Veradermics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Veradermics presently has a consensus target price of $153.00, suggesting a potential upside of 46.90%. Seaport Therapeutics has a consensus target price of $37.33, suggesting a potential upside of 62.60%. Given Seaport Therapeutics' higher probable upside, analysts clearly believe Seaport Therapeutics is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Seaport Therapeutics had 12 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Seaport Therapeutics and 2 mentions for Veradermics. Veradermics' average media sentiment score of 1.48 beat Seaport Therapeutics' score of 0.85 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seaport Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Seaport Therapeutics	N/A	N/A	N/A

Summary

Veradermics beats Seaport Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Seaport Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Seaport Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Seaport Therapeutics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Seaport Therapeutics	N/A	N/A	N/A

Tarsus Pharmaceuticals has higher revenue and earnings than Seaport Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.61	-$66.42M	-$1.09	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Tarsus Pharmaceuticals currently has a consensus price target of $92.57, suggesting a potential upside of 18.33%. Seaport Therapeutics has a consensus price target of $37.33, suggesting a potential upside of 62.60%. Given Seaport Therapeutics' higher probable upside, analysts clearly believe Seaport Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Seaport Therapeutics had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 14 mentions for Seaport Therapeutics and 12 mentions for Tarsus Pharmaceuticals. Seaport Therapeutics' average media sentiment score of 0.85 beat Tarsus Pharmaceuticals' score of 0.62 indicating that Seaport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seaport Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Seaport Therapeutics beats Tarsus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Seaport Therapeutics compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Organon & Co. has higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.76
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Organon & Co. has a net margin of 3.41% compared to Seaport Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Seaport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Seaport Therapeutics	N/A	N/A	N/A

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 16.64%. Seaport Therapeutics has a consensus target price of $37.33, suggesting a potential upside of 62.60%. Given Seaport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seaport Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Seaport Therapeutics had 8 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Seaport Therapeutics and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.05 beat Seaport Therapeutics' score of 0.85 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Seaport Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Organon & Co. beats Seaport Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Seaport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPTX vs. The Competition

Export

Metric	Seaport Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.32B	$12.43B	$7.21B	$15.01B
Dividend Yield	N/A	2.63%	2.57%	12.21%
P/E Ratio	-1.89	789.61	272.84	25.31
Price / Sales	N/A	952.99	701.69	107.35
Price / Cash	N/A	89.50	77.71	51.48
Price / Book	N/A	10.41	10.37	6.18
Net Income	-$74.88M	$2.83B	$3.49B	$357.96M
7 Day Performance	5.56%	-1.51%	-0.76%	-0.56%
1 Month Performance	-5.20%	0.80%	-0.39%	-3.62%
1 Year Performance	N/A	3.96%	18.93%	6.05%

Seaport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPTX Seaport Therapeutics	2.8447 of 5 stars	$22.96 -7.0%	$37.33 +62.6%	N/A	$1.32B	N/A	N/A	58	News Coverage Positive News
DFTX Definium Therapeutics	2.9983 of 5 stars	$38.09 +0.2%	$63.00 +65.4%	+285.5%	$5.12B	N/A	N/A	40	Trending News Analyst Forecast Options Volume
INDV Indivior	4.1523 of 5 stars	$34.94 +0.3%	$45.17 +29.3%	+47.6%	$4.12B	$1.24B	12.52	1,051	Positive News
MANE Veradermics	2.7355 of 5 stars	$98.36 +0.6%	$153.00 +55.6%	N/A	$4.12B	N/A	N/A	19	Analyst Forecast
TARS Tarsus Pharmaceuticals	2.4872 of 5 stars	$90.78 +9.1%	$90.50 -0.3%	+57.8%	$3.98B	$451.36M	N/A	50	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPTX) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seaport Therapeutics (SPTX) Competitors

SPTX vs. DFTX, INDV, MANE, TARS, and OGN

How does Seaport Therapeutics compare to Definium Therapeutics?

Summary

How does Seaport Therapeutics compare to Indivior?

Summary

How does Seaport Therapeutics compare to Veradermics?

Summary

How does Seaport Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Seaport Therapeutics compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX vs. The Competition

Seaport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seaport Therapeutics (SPTX) Competitors

SPTX vs. DFTX, INDV, MANE, TARS, and OGN

How does Seaport Therapeutics compare to Definium Therapeutics?

Does the media favor DFTX or SPTX?

Do analysts prefer DFTX or SPTX?

Which has preferable valuation & earnings, DFTX or SPTX?

Do institutionals and insiders hold more shares of DFTX or SPTX?

Is DFTX or SPTX more profitable?

Summary

How does Seaport Therapeutics compare to Indivior?

Does the media favor SPTX or INDV?

Do insiders & institutionals believe in SPTX or INDV?

Do analysts rate SPTX or INDV?

Is SPTX or INDV more profitable?

Which has stronger valuation and earnings, SPTX or INDV?

Summary

How does Seaport Therapeutics compare to Veradermics?

Which has higher valuation and earnings, MANE or SPTX?

Do analysts prefer MANE or SPTX?

Does the media favor MANE or SPTX?

Is MANE or SPTX more profitable?

Summary

How does Seaport Therapeutics compare to Tarsus Pharmaceuticals?

Is TARS or SPTX more profitable?

Which has higher earnings and valuation, TARS or SPTX?

Do analysts rate TARS or SPTX?

Do institutionals & insiders believe in TARS or SPTX?

Does the media prefer TARS or SPTX?

Summary

How does Seaport Therapeutics compare to Organon & Co.?

Which has preferable valuation and earnings, OGN or SPTX?

Is OGN or SPTX more profitable?

Do insiders & institutionals believe in OGN or SPTX?

Do analysts rate OGN or SPTX?

Does the media refer more to OGN or SPTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX vs. The Competition

Seaport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools